Updated: Managing RA

This is the lay version of the EULAR recommendations for the management of rheumatoid arthritis using synthetic and biologic disease-modifying antirheumatic drugs. The original publication can be downloaded from the EULAR website: www.eular.org. Smolen JS, Landewé RBM, Bergstra SA, et alEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: […]

Read More…

Favourable balance of benefit and harm for prednisolone in older RA patients

Add-on low-dose prednisolone has beneficial long-term effects in seniors with established rheumatoid arthritis INTRODUCTION Rheumatoid arthritis is a chronic inflammatory disease that affects a person’s joints, and may cause pain and disability. Rheumatoid arthritis can affect people of all ages, but it most often starts between the ages of 40 and 60. Rheumatoid arthritis is […]

Read More…

High steroid-free success rates after glucocorticoid bridging

90% of people with early rheumatoid arthritis are steroid-free 2 years after bridging therapy INTRODUCTION Rheumatoid arthritis is a chronic inflammatory disease that affects a person’s joints, and may cause pain and disability. Rheumatoid arthritis can affect people of all ages, but it most often starts between the ages of 40 and 60. Rheumatoid arthritis […]

Read More…

Updated: COVID-19 vaccination recommendations in RMDs

This is the lay version of the EULAR recommendations for COVID-19 vaccination in people with rheumatic and musculoskeletal diseases. The original publication can be downloaded from the EULAR website: www.eular.org. Landewé RBM, Kroon FPB, Alunno A, et al. EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context […]

Read More…

Full vaccination course is necessary for efficient response

People with inflammatory arthritis may have impaired response to the first dose but excellent final responses to mRNA vaccines. INTRODUCTION COVID-19 is the disease caused by a new type of coronavirus called severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). It was declared a pandemic by the World Health Organization on 11 March 2020. COVID-19 has forced […]

Read More…

Risk of flare higher with hydroxychloroquine reduction or discontinuation

Decisions to maintain, reduce or stop SLE treatment may affect specific subgroups differently. INTRODUCTION Systemic lupus erythematosus (often called Lupus or SLE) is an autoimmune disease. It often starts in women between the ages of 15 and 45, but it can occur at any age, and 10% of patients are male. SLE symptoms can vary. […]

Read More…

Predicting treatment success in rheumatoid arthritis

Particularly in early disease, prediction can be achieved for people with lower baseline levels of diseases activity INTRODUCTION Rheumatoid arthritis is a chronic inflammatory disease that affects a person’s joints, and may cause pain and disability. Rheumatoid arthritis can affect people of all ages, but it most often starts between the ages of 40 and […]

Read More…

Over time, joint swelling recurs in the same joints in people with RA

The results suggest that local factors influence joint inflammation over time. INTRODUCTION Rheumatoid arthritis is a chronic inflammatory disease that affects a person’s joints, and may cause pain and disability. Rheumatoid arthritis can affect people of all ages, but it most often starts between the ages of 40 and 50 – although this can depend […]

Read More…

Steroid dose and duration linked to cardiovascular events in RA

Dose and duration are associated with an increased risk for incident cardiovascular events in steroid-naïve patients INTRODUCTION Rheumatoid arthritis is a chronic inflammatory disease that affects a person’s joints, and may cause pain and disability. Rheumatoid arthritis can affect people of all ages, but it most often starts between the ages of 30 and 50 […]

Read More…

Update: Using rheumatology drugs for COVID-19

This is the lay version of the EULAR points to consider on the use of medicines traditionally used in rheumatology to treat the inflammation seen in people with severe COVID-19. The original publication can be downloaded from the EULAR website: www.eular.org. Alunno A, et al. 2021 update of the EULAR points to consider on the […]

Read More…